•  
  •  
  •  
  •  

2026-07-25 04:14:05

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%

Keywords Selected:  LaurusLabs

Research

  • Q4FY22 Result Update – Laurus Labs - ICICI Direct

Stock Report

  • Laurus Labs Reports Exceptional Q1 FY27 Results: Consolidated Net Profit Surges 126% YoY to ₹362 Crore; EBITDA Margins Expand to 31.8%
  • Laurus Labs Limited recommends 2nd interim dividend of Rs. 1.20
  • Laurus Labs Ltd Q4 FY2025-26 consolidated PAT increases to Rs. 279.14 crores
  • Laurus Labs Ltd reports consolidated net profit of Rs. 251.66 crores in Q3 FY2026
  • Laurus Labs Limited approves interim dividend of Rs. 0.80
  • Laurus Labs Ltd reports rise in Q2FY26 consolidated PAT to Rs. 194.97 crores
  • Laurus Labs Ltd allotted 531.77 acres of land by the Government of Andhra Pradesh
  • Laurus Labs Ltd consolidated Q1 FY2026 PAT at Rs. 163.02 crores
  • Laurus Labs Limited approves 2nd interim dividend of Rs. 0.80
  • Laurus Labs Ltd posts Rs. 232.77 crores consolidated PAT in Q4FY25
  • Laurus Labs Limited receives EIR for API facility Unit-4
  • Laurus Labs Ltd Q3 FY2025 consolidated net profit jumps to Rs. 92.30 crores
  • Laurus Labs Limited invests in Laurus Bio Pvt Ltd
  • Laurus Labs Ltd posts Rs. 19.84 crores consolidated PAT in Q2FY25
  • Laurus Labs Inaugurates New State of the Art R&D Facility at IKP Knowledge Park
  • Laurus Labs concludes successful USFDA audit for API Manufacturing Facility at Hyderabad
  • Laurus Labs Ltd posts consolidated PAT of Rs. 12.51 crores in Q1 FY2025
  • Laurus Labs Limited receives EIR from USFDA for API facilities
  • Laurus Labs Limited recommends 2nd interim dividend of Rs. 0.40
  • Laurus Labs Ltd Q4 FY24 consolidated net profit up QoQ at Rs. 75.61 crores
  • Laurus Labs Limited forms JV company
  • Laurus Labs enters into Joint Venture Agreement with KRKA, Slovenia
  • Laurus Labs Ltd posts Rs. 23.14 crores consolidated PAT in Q3 FY2024
  • Laurus Synthesis Pvt Ltd receives Form 483 with 5 observations from USFDA

Latest Post

  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025